Acipimox

Chemical formula: C₆H₆N₂O₃  Molecular mass: 154.125 g/mol  PubChem compound: 5310993

Active ingredient description

Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC Group Classification
C10AD06 Acipimox C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AD Nicotinic acid and derivatives
Discover more medicines within C10AD06

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Document Type Information Source  
 OLBETAM Capsule MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 51037-30-0
DrugBank Drug: DB09055
KEGG Drug: D07190
PubChem Compound: 5310993
RxNorm Ingredient: 16817
SNOMED-CT Concept: 391711008
Acipimox (substance)
UNII Identifier: K9AY9IR2SD
ACIPIMOX

Medicines

Acipimox is an active ingredient of these brands:

Netherlands (NL)

New Zealand (NZ)

Singapore (SG)

South Africa (ZA)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈